IP Library Granted Patent US 9,650,378
Granted Patent B2
US 9,650,378 · App. 15/045,652 · Granted May 16, 2017

(1-azinone)-substituted pyridoindoles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,378
App. No.
15/045,652
Granted
May 16, 2017
Kind
B2
Abstract

Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R 1 is H or optionally substituted alkyl; R 2 , R 3 , R 4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF 3 , and —CN; G is —CR 12 R 13 —NR 5 — or —NR 5 —CR 12 R 13 ; R 5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(═O)—R 6 , —C(═O)—O—R 7 , or —C(═O)—NR 19 R 20 ; R 6 and R 7 are each optionally substituted alkyl or optionally substituted heterocycle; R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 19 and R 20 are each independently selected from H or optionally substituted alkyl; R 14 and R 15 are each independently H or halogen; L is —CH 2 —O—, —CH 2 CH 2 —, —CH═CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.

Claims (53)

1. A compound of formula I:

wherein

R 1 is H or optionally substituted alkyl;

R 2 , R 3 , R 4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF 3 , and —CN;

G is —CR 12 R 13 —NR 5 — or —NR 5 —CR 12 R 13 ;

R 5 is H, optionally substituted alkyl;

R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from H or optionally substituted alkyl;

Y is CH;

L is —CH 2 —O—; and

B is heteroaryl.

2. A compound according to claim 1 wherein G is —CH 2 —NR 5 —.

3. A compound according to claim 1 wherein G is —NR 5 —CH 2 —.

4. A compound according to claim 1 wherein R 5 is H.

5. A compound according to claim 1 wherein R 5 is optionally substituted alkyl.

6. A compound according to claim 5 wherein R 5 is selected from methyl, ethyl, 2-propyl, 2-hydroxyethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl and 2-oxo-2-(pyrrolidin-1-yl)ethyl, 2-(pyrrolidin-1-yl)ethyl and (S)-pyrrolidin-2-ylmethyl.

7. A compound according to claim 1 wherein R 1 is H.

8. A compound according to claim 1 wherein R 1 is alkyl.

9. A compound according to claim 8 wherein R 1 is selected from methyl and ethyl.

10. A compound according to claim 1 wherein L is —CH 2 —O—.

11. A compound according to claim 1 wherein B is heteroaryl.

12. A compound according to claim 11 wherein B is pyridinyl.

13. A compound according to claim 12 wherein B is pyridin-2-yl.

14. A compound according to claim 12 wherein B is pyridin-3-yl.

15. A compound according to claim 11 wherein B is pyridazinyl.

16. A compound according to claim 15 wherein B is pyridazin-3-yl.

17. A compound according to claim 11 wherein B is pyrimidinyl.

18. A compound according to claim 17 wherein B is pyrimidin-5-yl.

19. A compound according to claim 17 wherein B is pyrimidin-2-yl.

20. A compound according to claim 1 wherein B, together with R 2 , R 3 and R 4 , is selected from pyridin-2-yl, 5-chloropyridin-2-yl, 5-(trifluoromethyl)pyridin-2-yl, 5-fluoropyridin-2-yl, 6-(trifluoromethyl)pyridazin-3-yl, 6-methylpyridazin-3-yl, 6-(trifluoromethyl)pyridin-3-yl, 2-(trifluoromethyl)pyrimidin-5-yl, 5-(trifluoromethyl)pyrimidin-2-yl, 5-methylpyridin-2-yl, 6-methylpyridin-3-yl, pyrimidin-2-yl, imidazo[1,2-α]pyridin-6-yl, imidazo[1,2-α]pyridin-2-yl.

21. A compound according to claim 1 wherein the compound is selected from,

22. A compound according to claim 1 wherein at least one of R 8 and R 9 is H.

23. A compound according to claim 1 wherein at least one of R 8 and R 9 is alkyl.

24. A compound according to claim 23 wherein at least one of R 8 and R 9 is methyl.

25. A compound according to claim 1 wherein R 10 is alkyl.

26. A compound according to claim 25 wherein R 10 is methyl.

27. A compound according to claim 1 wherein R 11 is alkyl.

28. A compound according to claim 27 wherein R 11 is methyl.

29. A compound according to claim 1 wherein R 12 is alkyl.

30. A compound according to claim 29 wherein R 12 is methyl.

31. A compound according to claim 1 wherein R 13 is alkyl.

32. A compound according to claim 31 wherein R 13 is methyl.

33. A compound according to claim 1 wherein R 10 , R 11 , R 12 and R 13 are each methyl.

34. A compound according to claim 1 wherein

G is —CH 2 —NR 5 — or —NR 5 —CH 2 —;

R 1 and R 5 are each independently H or methyl;

B is heteroaryl; and when L is —CH 2 —O—; then R 2 , R 3 , R 4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF 3 , and —CN.

35. A compound according to claim 1 wherein the compound is in a pharmaceutically acceptable salt form.

36. A compound according to claim 35 wherein the salt is an HCl salt.

37. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, excipient or diluent therefore.

38. A method of treating obesity, comprising administering to a patient in need of obesity reduction an obesity-reducing effective amount of a compound according to claim 1 .

39. A method of treating anxiety, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1 .

40. A method of treating depression, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1 .

41. A method of treating non-alcoholic fatty liver disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1 .

Assignments (12)
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 18, 2026
From: HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.)
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075642/0639 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: HARMONY BIOSCIENCES, LLC
Reel/Frame 073383/0559 →
ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON SEPTEMBER 1, 2017, AT REEL/FRAME 043746/0621 Recorded Mar 17, 2025
From: BARCLAYS BANK PLC, AS EXISTING AGENT
To: APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT
Reel/Frame 070531/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2024
From: HARMONY BIOSCIENCES, LLC
To: HARMONY BIOSCIENCES MANAGEMENT, INC.
Reel/Frame 069297/0828 →
CHANGE OF NAME Recorded Apr 22, 2024
From: ALBANY MOLECULAR RESEARCH, INC.
To: CURIA GLOBAL, INC.
Reel/Frame 067186/0720 →
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Jul 27, 2023
From: HARMONY BIOSCIENCES, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064417/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2023
From: GUZZO, PETER ROBERT; SURMAN, MATTHEW DAVID; HENDERSON, ALAN JOHN; JIANG, MAY XIAOWU; HADDEN, MARK; GRABOWSKI, JAMES; USYATINSKY, ALEXANDER
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 064391/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2021
From: CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.)
To: HARMONY BIOSCIENCES, LLC
Reel/Frame 057163/0596 →
SECURITY INTEREST Recorded Aug 9, 2021
From: HARMONY BIOSCIENCES, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057120/0282 →
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2020
From: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
Reel/Frame 054252/0687 →
FIRST LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC-BY ITS SOLE MEMBER: ALO ACQUISITION LLC
To: BARCLAYS BANK, PLC AS COLLATERAL AGENT
Reel/Frame 043746/0621 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING LLC-BY ITS SOLE MEMBER:ALO ACQUISITION LLC
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 043746/0657 →